Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mirum Pharmaceuticals ( (MIRM) ) has shared an announcement.
On January 12, 2026, Mirum Pharmaceuticals reported preliminary, unaudited 2025 net product sales of about $520 million, surpassing the upper end of its guidance, driven by strong growth from LIVMARLI, CHOLBAM and CTEXLI, alongside positive cash flow from operations and an expected year-end 2025 cash and investments balance of roughly $392 million. The company outlined 2026 sales guidance of $630 million to $650 million and highlighted a series of late-stage clinical and regulatory milestones, including ongoing Phase 3 programs for volixibat in primary sclerosing cholangitis and primary biliary cholangitis, accelerated timelines for the LIVMARLI EXPAND study, and the proposed acquisition of Bluejay Therapeutics to add brelovitug for chronic hepatitis delta virus, signaling both robust commercial momentum and a deepening pipeline in rare liver and related diseases.
The most recent analyst rating on (MIRM) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
Mirum Pharmaceuticals’ overall score is driven by strong earnings call results and strategic corporate events, indicating growth potential. However, financial performance and valuation concerns, including high leverage and negative profitability, weigh down the score. Technical indicators suggest a positive trend but warrant caution due to overbought signals.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals, based in Foster City, California, is a rare disease-focused biopharmaceutical company specializing in therapies for cholestatic and other rare liver diseases, as well as select genetic and metabolic disorders. Its commercial portfolio includes LIVMARLI for pediatric cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM for bile acid synthesis and peroxisomal disorders, and CTEXLI for cerebrotendinous xanthomatosis, with an expanding global footprint that reached commercial access in 33 countries by the end of 2025.
Average Trading Volume: 670,454
Technical Sentiment Signal: Buy
Current Market Cap: $4.22B
For detailed information about MIRM stock, go to TipRanks’ Stock Analysis page.